Not recruiting

Study on the Safety and Effects of IPH6501 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Verified siteInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Non-Hodgkin Lymphoma, specifically in patients whose disease has returned or not responded to previous treatments. The trial will investigate a new treatment called IPH6501, which is given as a solution through an infusion into the vein. The main goal of the study is to understand how safe and tolerable this new treatment is for patients, and to see if it has any effect on the cancer.

The study will be conducted in two phases. In the first phase, different doses of IPH6501 will be tested to find the safest and most effective dose. In the second phase, the treatment will be given to more patients to further evaluate its safety and potential benefits. Throughout the study, researchers will closely monitor patients for any side effects and how their cancer responds to the treatment.

Participants in this study will have a type of Non-Hodgkin Lymphoma that expresses a protein called CD20. This includes several subtypes of the disease, such as Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. The study aims to provide valuable information about the new treatment, which could help in developing better therapies for this challenging condition in the future.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial assessment
Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and previous treatments for non-Hodgkin lymphoma.
Eligibility criteria include having relapsed or refractory CD20-expressing non-Hodgkin lymphoma, having received at least two prior systemic therapies, and having a measurable disease.
Step 2
Treatment phase 1
The first phase involves dose finding to determine the maximum tolerated dose of IPH6501. This is administered as an intravenous (IV) infusion.
The frequency and duration of the infusion are determined based on the safety and tolerability observed during this phase.
Step 3
Treatment phase 2
In the second phase, the recommended dose from phase 1 is used to further evaluate the treatment's effects.
This phase focuses on expanding the dose to a larger group of participants to assess the preliminary antineoplastic activity of IPH6501.
Step 4
Monitoring and follow-up
Throughout the trial, regular monitoring is conducted to assess safety, tolerability, and any side effects.
Follow-up visits are scheduled to evaluate the treatment's impact on the disease and to perform necessary tests.
Step 5
End of trial
The trial is estimated to conclude by February 27, 2027.
Final assessments are conducted to gather data on the efficacy and safety of IPH6501.

Who can join the trial?

7 criteria

Patients must have a type of cancer called **Non-Hodgkin's Lymphoma (NHL)** that has come back or is not responding to treatment. This includes specific types like **Diffuse Large B Cell Lymphoma**, **High-grade B-cell lymphoma**, **Primary mediastinal large B-cell lymphoma**, **Follicular Lymphoma**, **Mantle cell lymphoma**, and **Marginal zone lymphoma**.
Patients must have tried at least two different treatments before, including a treatment with an **anti-CD20 antibody** like rituximab, possibly combined with chemotherapy, or have relapsed after a procedure called **autologous stem cell rescue**.
Patients must be at least 18 years old.
Patients must have a tumor that can be measured. This means having at least one lymph node that is more than 1.5 cm in its longest dimension or a tumor outside the lymph nodes that is more than 1.0 cm in its longest dimension.
Patients must be able to perform daily activities with some limitations, as measured by a scale called the **Eastern Cooperative Oncology Group (ECOG) performance status**, which should be 2 or less.
Patients must be expected to live for at least 12 more weeks.
Any side effects from previous treatments must be stable and have improved to a mild level, except for non-serious side effects like hair loss.

Who cannot join the trial?

10 criteria

Patients who have a different type of cancer that is not **CD20-expressing Non-Hodgkin Lymphoma**.
Patients who are not experiencing a return of their cancer (**relapsed**) or whose cancer is not resistant to treatment (**refractory**).
Patients who are not within the specified age range for the study.
Patients who are not able to follow the study procedures or do not agree to participate.
Patients who have other medical conditions that might interfere with the study or make it unsafe for them to participate.
Patients who are pregnant or breastfeeding.
Patients who are participating in another clinical trial at the same time.
Patients who have had certain treatments recently that might affect the study results.
Patients who have allergies or reactions to the study medication or similar drugs.
Patients who have a history of certain heart, liver, or kidney problems.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Centre Hospitalier Lyon Sud
Verified
Pierre Benite, France
Centre Hospitalier Universitaire De Lille
Verified
Lille, France
Centre Hospitalier Universitaire De Nantes
Verified
Nantes, France

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

IPH6501 is an investigational medication being studied for its potential to treat patients with a type of cancer called Non-Hodgkin Lymphoma, specifically when the cancer has returned or has not responded to previous treatments. This medication is designed to target and act against cancer cells that express a protein known as CD20. The trial aims to understand how safe and tolerable IPH6501 is for patients, as well as to determine the most effective dose to use in future studies.

Iph6501

What is already known about the treatment

IPH6501 – This medication is administered intravenously and is currently being studied in clinical trials for its safety and effectiveness in treating relapsed or refractory CD20-expressing Non-Hodgkin Lymphoma. It is in the early stages of research, with ongoing studies to determine the appropriate dosage and potential side effects. The main therapeutic use of IPH6501 is to target and treat certain types of lymphoma that have not responded to previous treatments. At the molecular level, it works by binding to the CD20 protein on the surface of cancer cells, which may help the immune system to recognize and destroy these cells. It is classified as an antineoplastic agent, which means it is designed to prevent the growth and spread of cancer cells.

Investigated diseases

Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma – This is a type of cancer that affects the lymphatic system, specifically involving B-cells that express the CD20 protein. It is characterized by the return or persistence of the disease after initial treatment. The lymphoma cells grow uncontrollably, forming tumors in the lymph nodes and potentially spreading to other parts of the body. Symptoms may include swollen lymph nodes, fever, night sweats, and weight loss. The disease can vary in its rate of progression, with some forms being more aggressive than others. It requires ongoing monitoring to assess changes in the disease's behavior.